Literature DB >> 22002003

A case-control histological study on the effects of phlebotomy in patients with chronic hepatitis C.

Massimo Sartori1, Silvano Andorno, Angelo Rossini, Renzo Boldorini, Cristina Bozzola, Stefania Carmagnola, Mario Del Piano, Emanuele Albano.   

Abstract

OBJECTIVE: The aim of this study was to assess the actual effectiveness of long-term phlebotomy by comparing histological improvement (HI) in 69 Caucasian HCV-RNA-positive CHC patients undergoing phlebotomy or receiving an interferon-based therapy without virological response [nonresponders to interferon therapy(IBT-NR)].
METHODS: HI was defined by at least one point reduction of the staging score or, in the case of unchanged stage, by at least two points reduction of the grading score (Knodel's Activity Index) and was retrospectively evaluated by comparing two consecutive (56 ± 28 months apart) liver biopsies from 30 phlebotomized and 39 IBT-NR patients.
RESULTS: HI was observed in 15 of 30 (50%) patients treated with phlebotomy and in six of 39 (15%) IBT-NR subjects (P=0.002). Furthermore, AST, ALT, and GGT serum levels were significantly reduced only in phlebotomized patients (P ≤ 0.003) at the time of the second biopsy. Univariate and multivariate analysis showed that histological grading score before therapy (P=0.001) and phlebotomy (P=0.002) were independently predictors of HI.
CONCLUSION: HI induced by long-term phlebotomy effectively exceeds that spontaneously occurring in patients IBT-NR confirming the efficacy of iron depletion in attenuating CHC progression when other therapies have failed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002003     DOI: 10.1097/MEG.0b013e328349923c

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

Review 1.  Current applications of therapeutic phlebotomy.

Authors:  Tarek Bou Assi; Elizabeth Baz
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

2.  Serum ferritin and the risk of hepatocellular carcinoma in chronic liver disease of viral etiology: a case-control study.

Authors:  Prachi S Patil; K M Mohandas; Shobna J Bhatia; Shaesta A Mehta
Journal:  Indian J Gastroenterol       Date:  2013-09-05

Review 3.  Hepatitis C, porphyria cutanea tarda and liver iron: an update.

Authors:  F Ryan Caballes; Hossein Sendi; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2012-04-17       Impact factor: 5.828

Review 4.  Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation.

Authors:  Tomohide Hori; Yasuharu Onishi; Hideya Kamei; Nobuhiko Kurata; Masatoshi Ishigami; Yoji Ishizu; Yasuhiro Ogura
Journal:  Ann Gastroenterol       Date:  2016-07-08

Review 5.  Gamma-Glutamyltransferase: A Predictive Biomarker of Cellular Antioxidant Inadequacy and Disease Risk.

Authors:  Gerald Koenig; Stephanie Seneff
Journal:  Dis Markers       Date:  2015-10-12       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.